Cited 35 times in
Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김종윤 | - |
dc.contributor.author | 이상학 | - |
dc.contributor.author | 장양수 | - |
dc.contributor.author | 정남식 | - |
dc.contributor.author | 최동훈 | - |
dc.contributor.author | 허애영 | - |
dc.contributor.author | 강석민 | - |
dc.date.accessioned | 2015-04-23T16:40:21Z | - |
dc.date.available | 2015-04-23T16:40:21Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 1074-2484 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/101009 | - |
dc.description.abstract | The aim of this study was to compare the effects of 3 different statin regimens that have equivalent low-density lipoprotein cholesterol (LDL-C) lowering efficacy on the apolipoprotein B/A1 ratio and glucose metabolism. After a 4-week dietary lead-in, 90 hypercholeserolemic patients were randomly assigned to 1 of 3 treatment groups for 8 weeks: atorvastatin 20 mg, rosuvastatin 10 mg, or atorvastatin/ezetimibe 5 mg/5 mg. At drug treatment week 8, we compared the percentage changes in lipid parameters, apolipoprotein B/A1 ratio, hemoglobin A1c, and homeostasis model assessment-insulin resistance (HOMA-IR) from baseline. Seventy-six patients completed the study and the percentage changes in LDL-C were comparable among the groups. However, the percentage reduction in the apolipoprotein B/A1 ratio was significantly greater in the rosuvastatin group (-47% +/- 14%, P = .04) and the combination group (-46% +/- 8%, P = .05) than in the atorvastatin group (-39% +/- 11%). The percentage increase in hemoglobin A1c was small but significantly greater in the atorvastatin group compared to the combination group (3.0% +/- 5.2% and -0.4% +/- 4.0%, P = .03). The effect of rosuvastatin on hemoglobin A1c was not different from those of the other 2 regimens. The effects of 3 statin regimens were similar on HOMA-IR. In conclusion, 3 statin regimens have differential effect on apolipoprotein B/A1 and glycemic control after comparable LDL-C reduction. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 167~174 | - |
dc.relation.isPartOf | JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Anticholesteremic Agents/administration & dosage | - |
dc.subject.MESH | Anticholesteremic Agents/adverse effects | - |
dc.subject.MESH | Anticholesteremic Agents/therapeutic use* | - |
dc.subject.MESH | Apolipoprotein A-I/blood | - |
dc.subject.MESH | Apolipoproteins B/blood | - |
dc.subject.MESH | Atorvastatin Calcium | - |
dc.subject.MESH | Azetidines/administration & dosage | - |
dc.subject.MESH | Azetidines/adverse effects | - |
dc.subject.MESH | Azetidines/therapeutic use* | - |
dc.subject.MESH | Blood Glucose/analysis | - |
dc.subject.MESH | Body Mass Index | - |
dc.subject.MESH | Cholesterol/blood | - |
dc.subject.MESH | Cholesterol, LDL/blood* | - |
dc.subject.MESH | Drug Combinations | - |
dc.subject.MESH | Ezetimibe, Simvastatin Drug Combination | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorobenzenes/administration & dosage | - |
dc.subject.MESH | Fluorobenzenes/adverse effects | - |
dc.subject.MESH | Fluorobenzenes/therapeutic use* | - |
dc.subject.MESH | Glucose/metabolism* | - |
dc.subject.MESH | Glycated Hemoglobin A/analysis | - |
dc.subject.MESH | Heptanoic Acids/administration & dosage | - |
dc.subject.MESH | Heptanoic Acids/adverse effects | - |
dc.subject.MESH | Heptanoic Acids/therapeutic use* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Pyrimidines/administration & dosage | - |
dc.subject.MESH | Pyrimidines/adverse effects | - |
dc.subject.MESH | Pyrimidines/therapeutic use* | - |
dc.subject.MESH | Pyrroles/administration & dosage | - |
dc.subject.MESH | Pyrroles/adverse effects | - |
dc.subject.MESH | Pyrroles/therapeutic use* | - |
dc.subject.MESH | Rosuvastatin Calcium | - |
dc.subject.MESH | Simvastatin/administration & dosage | - |
dc.subject.MESH | Simvastatin/adverse effects | - |
dc.subject.MESH | Simvastatin/therapeutic use* | - |
dc.subject.MESH | Sulfonamides/administration & dosage | - |
dc.subject.MESH | Sulfonamides/adverse effects | - |
dc.subject.MESH | Sulfonamides/therapeutic use* | - |
dc.title | Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Ae-Young Her | - |
dc.contributor.googleauthor | Jong-Youn Kim | - |
dc.contributor.googleauthor | Seok-Min Kang | - |
dc.contributor.googleauthor | Donghoon Choi | - |
dc.contributor.googleauthor | Yangsoo Jang | - |
dc.contributor.googleauthor | Namsik Chung | - |
dc.contributor.googleauthor | Ichiro Manabe | - |
dc.contributor.googleauthor | Sang-Hak Lee | - |
dc.identifier.doi | 10.1177/1074248409357922 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00926 | - |
dc.contributor.localId | A03448 | - |
dc.contributor.localId | A03585 | - |
dc.contributor.localId | A04053 | - |
dc.contributor.localId | A04357 | - |
dc.contributor.localId | A00037 | - |
dc.contributor.localId | A02833 | - |
dc.relation.journalcode | J01297 | - |
dc.identifier.eissn | 1940-4034 | - |
dc.identifier.pmid | 20147603 | - |
dc.identifier.url | http://cpt.sagepub.com/content/15/2/167 | - |
dc.subject.keyword | atorvastatin | - |
dc.subject.keyword | rosuvastatin | - |
dc.subject.keyword | ezetimibe | - |
dc.subject.keyword | apolipoproteins | - |
dc.subject.keyword | glucose | - |
dc.contributor.alternativeName | Kim, Jong Youn | - |
dc.contributor.alternativeName | Lee, Sang Hak | - |
dc.contributor.alternativeName | Jang, Yang Soo | - |
dc.contributor.alternativeName | Chung, Nam Sik | - |
dc.contributor.alternativeName | Choi, Dong Hoon | - |
dc.contributor.alternativeName | Her, Ae Young | - |
dc.contributor.alternativeName | Kang, Seok Min | - |
dc.contributor.affiliatedAuthor | Kim, Jong Youn | - |
dc.contributor.affiliatedAuthor | Jang, Yang Soo | - |
dc.contributor.affiliatedAuthor | Chung, Nam Sik | - |
dc.contributor.affiliatedAuthor | Choi, Dong Hoon | - |
dc.contributor.affiliatedAuthor | Her, Ae Young | - |
dc.contributor.affiliatedAuthor | Kang, Seok Min | - |
dc.contributor.affiliatedAuthor | Lee, Snag Hak | - |
dc.citation.volume | 15 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 167 | - |
dc.citation.endPage | 174 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, Vol.15(2) : 167-174, 2010 | - |
dc.identifier.rimsid | 54508 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.